Identifying KOLs in Growing and Emerging MarketsThe process of discovering HCPs who are leading key opinion leaders (KOLs) in emerging and growing markets is Share XIdentifying KOLs in Growing and Emerging Marketshttps://pharmaphorum.com/partner-content/identifying-kols-in-growing-and-emerging-markets/
ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
Rome Therapeutics raises $77m for junk DNA-targeting drugsStartup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which Share XRome Therapeutics raises $77m for junk DNA-targeting drugshttps://pharmaphorum.com/news/rome-therapeutics-raises-77m-for-junk-dna-targeting-drugs/
France’s biotech ecosystem is primed for growth – it’s time to feed itAfter some years of stagnant funding and growth France is now at an inflection point for health care Share XFrance’s biotech ecosystem is primed for growth – it’s time to feed ithttps://pharmaphorum.com/r-d/france-biotech-ecosystem-jeito-capital/
Biotech Insight podcast: Overcoming planning challenges in oncologyThe first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges Share XBiotech Insight podcast: Overcoming planning challenges in oncologyhttps://pharmaphorum.com/podcast/biotech-insight-oncology-planning/
Health Innovators: PureTech Health’s Daphne ZoharIn latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the Share XHealth Innovators: PureTech Health’s Daphne Zoharhttps://pharmaphorum.com/r-d/health-innovators-daphne-zohar-puretech/
Imugene HER2 vaccine hits target in stomach cancer trialA peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive Share XImugene HER2 vaccine hits target in stomach cancer trialhttps://pharmaphorum.com/news/imugene-her2-vaccine-hits-target-in-stomach-cancer-trial/
UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financingThe UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing Share XUK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financinghttps://pharmaphorum.com/news/uk-biotech-booming-as-sector-rakes-in-1-6bn-in-q2-financing/
Pharma’s use of synthetic biology could deliver radical innovationSynthetic biology holds much promise for the life sciences sector as it continues to look for new ways Share XPharma’s use of synthetic biology could deliver radical innovationhttps://pharmaphorum.com/r-d/pharma-synthetic-biology-radical-innovation/
